v3.19.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Product sales, net $ 2,257,851 $ 2,428,498 $ 4,173,759 $ 4,234,103
Cost of products sold 752,183 1,021,573 1,370,876 1,584,250
Gross profit 1,505,668 1,406,925 2,802,883 2,649,853
Selling, general and administrative expenses 2,517,970 2,821,837 4,627,023 5,840,601
Research and development expenses 95,529 9,775 101,875 235,592
Total operating expenses 2,613,499 2,831,612 4,728,898 6,076,193
Loss from operations (1,107,831) (1,424,687) (1,926,015) (3,426,340)
Other expenses (2,563) (1,756) (4,825) (3,457)
Interest income 188 1,926 1,207 4,590
Change in fair value of derivative liability 12,462 52,722
Loss before provision for income taxes and net losses of equity investments (1,097,744) (1,424,517) (1,876,911) (3,425,207)
Provision for income taxes (14,163) (4,075) (18,627) (15,538)
Loss before equity in net earnings (losses) of equity investments (1,111,907) (1,428,592) (1,895,538) (3,440,745)
Income from earnings on China joint venture (58,664) (78,591) (49,100) (115,374)
Net loss (1,053,243) (1,350,001) (1,846,437) (3,325,371)
Net loss attributable to noncontrolling interests 11,959 6,994 22,402 108,657
Net loss attributable to Milestone Scientific Inc. $ (1,041,284) $ (1,343,007) $ (1,824,036) $ (3,216,714)
Net loss per share applicable to common stockholders—        
Basic (in dollars per share) $ (0.02) $ (0.04) $ (0.04) $ (0.09)
Diluted (in dollars per share) $ (0.02) $ (0.04) $ (0.04) $ (0.09)
Weighted average shares outstanding and to be issued—        
Basic (in shares) 45,366,237 35,297,906 41,904,581 34,939,306
Diluted (in shares) 45,366,237 35,297,906 41,904,581 34,939,306

Source